OVID vs. CRBP, OKYO, CHRS, WHWK, VIRI, MGNX, OCX, ZNTL, FBRX, and BYSI
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Corbus Pharmaceuticals (CRBP), OKYO Pharma (OKYO), Coherus Oncology (CHRS), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), MacroGenics (MGNX), OncoCyte (OCX), Zentalis Pharmaceuticals (ZNTL), Forte Biosciences (FBRX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.
Ovid Therapeutics vs. Its Competitors
Ovid Therapeutics (NASDAQ:OVID) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ovid Therapeutics currently has a consensus target price of $3.13, indicating a potential upside of 671.60%. Corbus Pharmaceuticals has a consensus target price of $50.88, indicating a potential upside of 515.18%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Corbus Pharmaceuticals.
Ovid Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. Ovid Therapeutics' return on equity of -34.17% beat Corbus Pharmaceuticals' return on equity.
Ovid Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500.
In the previous week, Ovid Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.51 beat Ovid Therapeutics' score of 0.92 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
Summary
Ovid Therapeutics beats Corbus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ovid Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OVID) was last updated on 7/12/2025 by MarketBeat.com Staff